Drug Search Results
More Filters [+]

Chlortalidone

Alternative Names: chlortalidone, chlorthalidone, higroton, hgp-1405, hgp 1405, hgp1405, thalitone, hygroton, edarbyclor, lopressidone, clorpres, demi-regroton, combipres, tenoretic 50, regroton, kerledex, tenoretic 100, tenoretic
Latest Update: 2024-11-19
Latest Update Note: Clinical Trial Update

Product Description

Chlorthalidone is a medication used in the management and treatment of hypertension. It is in the thiazide-like diuretics class of drugs. Chlorthalidone is a thiazide-like sulfonamide-derived diuretic that has been FDA approved since 1960 for the management of hypertension. It is also used in the treatment of edema (Sourced from: https://www.ncbi.nlm.nih.gov/books/NBK553174/)

Mechanisms of Action: NCCT Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Dominican Republic | Ecuador | Egypt | France | Germany | Greece | Hong Kong | Hungary | India | Ireland | Italy | Korea | Lebanon | Malaysia | Mexico | Morocco | Netherlands | New Zealand | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Serbia | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Venezuela | Vietnam

Approved Indications: Myocardial Infarction | Hypertension | Stroke | Liver Cirrhosis | Hypertension, Renal | Kidney Diseases | Nephrotic Syndrome | Edema | Myocardial Infarction | Hypertension | Stroke

Known Adverse Events: Hypotension | Dizziness

Company: Takeda
Company Location: TOKYO M0 103-8668
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Chlortalidone

Countries in Clinic: Brazil, Mexico

Active Clinical Trial Count: 2

Highest Development Phases

Phase 3: Hypertension

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

OPTION TREAT

P3

Recruiting

Hypertension

2023-12-31

SIL-30601-III-20(1)

P3

Completed

Hypertension

2023-08-15

95%

SIL-30601-III-20(1)

P3

Completed

Hypertension

2023-08-15

95%

Recent News Events